Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study
Qianhui Hua, Hangjie Zhang, Pingping Yao, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 19

Showing 19 citing articles:

Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis
Shiyao Xu, Jincheng Li, Hongyuan Wang, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 16
Application of Traditional Vaccine Development Strategies to SARS-CoV-2
Halie M. Rando, Ronan Lordan, Alexandra Lee, et al.
mSystems (2023) Vol. 8, Iss. 2
Open Access | Times Cited: 14
Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications, Efficacy, and Adverse Effects of Inactivated Whole-Virus COVID-19 Vaccines Sinopharm, CoronaVac, and Covaxin: An Observational Study
Sultan Ayoub Meo, Riham A. ElToukhy, Anusha Sultan Meo, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 826-826
Open Access | Times Cited: 13
A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2
Weiqi Wang, Shen Wang, Xianyong Meng, et al.
Antiviral Research (2024) Vol. 225, pp. 105854-105854
Closed Access | Times Cited: 4
Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults
Hangjie Zhang, Nani Xu, Yu Xu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 9
Evaluation of an RBD-nucleocapsid fusion protein as a booster candidate for COVID-19 vaccine
Bruno Vinicius Santos Valiate, Julia Castro, Tomás Gazzinelli Marçal, et al.
iScience (2024) Vol. 27, Iss. 7, pp. 110177-110177
Open Access | Times Cited: 2
Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up
Zafer Sezer, Shaikh Terkıs Islam Pavel, Ahmet İnal, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 140-140
Open Access | Times Cited: 1
The dynamics and determinants of specific systemic and mucosal antibody responses to SARS-CoV-2 in three adult cohorts in the Ecuadorian Andes: a study protocol
José E. Leon-Rojas, Tatiana Veloz, Jair Teran, et al.
F1000Research (2024) Vol. 11, pp. 1392-1392
Open Access | Times Cited: 1
COVID-19 antibody responses in individuals with natural immunity and with vaccination-induced immunity: a systematic review and meta-analysis
Qiuying Zhang, Lirui Jiao, Qiushi Chen, et al.
Systematic Reviews (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 1
An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines
Dona Susan Mathew, T. Pandya, HC Pandya, et al.
Biomolecules (2023) Vol. 13, Iss. 11, pp. 1565-1565
Open Access | Times Cited: 4
Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China
Yunyun Yi, Xiaoxu Han, Xinyu Cui, et al.
Vaccines (2023) Vol. 11, Iss. 6, pp. 1019-1019
Open Access | Times Cited: 3
Durability of immune response after SARS-CoV-2 vaccination in patients with chronic liver disease
Ruixin Song, Chao Yang, Qianqian Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Diverse immune responses in vaccinated individuals with and without symptoms after omicron exposure during the recent outbreak in Guangzhou, China
Ming Gao, Xiaomin Xing, Wenbiao Hao, et al.
Heliyon (2024) Vol. 10, Iss. 2, pp. e24030-e24030
Open Access
Immunogenicity, Safety, and Immune Persistence of One Dose of SARS-CoV-2 Recombinant Adenovirus Type-5 Vectored Vaccine in Children and Adolescents Aged 6–17 Years: An Immunobridging Trial
Xu Han, Mingwei Wei, Xiuyu Zheng, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 683-683
Open Access
COVID-19 Vaccination and Transient Increase in CD4/CD8 Cell Counts in People with HIV: Evidence from China
Yanyan Li, Yingying Lin, Yunyun Yi, et al.
Vaccines (2024) Vol. 12, Iss. 12, pp. 1365-1365
Open Access
Immune responses to inactivated COVID-19 vaccine were decreased in Chinese patients with chronic respiratory diseases
Lei Yang, LingFang Xu, Qiao Guo, et al.
International Journal of Medical Sciences (2023) Vol. 20, Iss. 6, pp. 737-748
Open Access | Times Cited: 1
A real-world study on the effectiveness of BBIBP-CorV and CoronaVac in Nanjing area
Huang Min, Jia Lu, Sheng Ye, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 1
Immunogenicity and safety of inactivated SARS‐CoV‐2 vaccines in people living with HIV: A longitudinal cohort study
Jie Li, Ling Nie, Caiping Guo, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 12
Closed Access | Times Cited: 1
The dynamics and determinants of specific systemic and mucosal antibody responses to SARS-CoV-2 in three adult cohorts in the Ecuadorian Andes: a study protocol
José E. Leon-Rojas, Tatiana Veloz, Jair Teran, et al.
F1000Research (2022) Vol. 11, pp. 1392-1392
Open Access | Times Cited: 1
Page 1

Scroll to top